SNS-595 AND METHODS OF USING THE SAME

1 - 37 . (canceled)

38 . A method for treating cancer comprising administering to a human patient having cancer a combination of: a) a therapeutically effective amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and b) a therapeutically effective amount of cytarabine.

39 . The method of claim 38 , wherein the amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid administered to the patient is about 30 mg/m 2 -75 mg/m 2 .

40 . The method of claim 38 , wherein the amount of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid administered to the patient is about 40 mg/m 2 -80 mg/m 2 .

41 . The method of claim 38 , wherein the amount of (+)-1,4-dihydro-7-[(3S,45)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid administered to the patient is about 50 mg/m 2 -90 mg/m 2 .

42 . The method of claim 38 , wherein the amount of cytarabine administered to the patient is at least 100 mg/m 2 .

43 . The method of claim 38 , wherein the cancer is leukemia.